Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/21075
Title: | Simvastatin impairs growth hormone-activated signal transducer and activator of transcription (STAT) signaling pathway in UMR-106 osteosarcoma cells | Authors: | Sandoval-Usme, M.C. Umaña-Pérez, A. Guerra, Borja Hernández-Perera, O. García Castellano, José Manuel Fernandez-Perez, Leandro Sánchez-Gómez, Myriam |
UNESCO Clasification: | 3209 Farmacología | Keywords: | Simvastatin Growth hormone Osteosarcoma cells |
Issue Date: | 2014 | Project: | Mecanismos Moleculares y Celulares de Señalización Intracelular en Respuesta A la Hormona de Crecimiento Humana: la Vía Jak (Janus Kinase) Stat (Signal Transducer And Activator Of Transcription) Co Estudio Funcional y Molecular de Las Proteínas Socs en Un Modelo de Resistencia Hepática A Insulina. |
Journal: | PLoS ONE | Abstract: | Recent studies have demonstrated that statins reduce cell viability and induce apoptosis in various types of cancer cells. The molecular mechanisms underlying these effects are poorly understood. The JAK/STAT pathway plays an important role in the regulation of proliferation and apoptosis in many tissues, and its deregulation is believed to be involved in tumorigenesis and cancer. The physiological activation of STAT proteins by GH is rapid but transient in nature and its inactivation is regulated mainly by the expression of SOCS proteins. UMR-106 osteosarcoma cells express a GH-responsive JAK2/STAT5 signaling pathway, providing an experimental model to study the influence of statins on this system. In this study we investigated the actions of simvastatin on cell proliferation, migration, and invasion on UMR-106 cells and examined whether alterations in GH-stimulated JAK/STAT/SOCS signaling may be observed. Results showed that treatment of osteosarcoma cells with simvastatin at 3 to 10 mM doses decreases cell proliferation, migration, and invasion in a timeand dose-dependent manner. At the molecular level, although the mechanisms used by simvastatin are not entirely clear, the effect of the statin on the reduction of JAK2 and STAT5 phosphorylation levels may partially explain the decrease in the GH-stimulated STAT5 transcriptional activity. This effect correlated with a time- and dose-dependent increase of SOCS-3 expression levels in cells treated with simvastatin, a regulatory role that has not been previously described. Furthermore, the finding that simvastatin is capable of inducing SOCS-3 and CIS genes expression shows the potential of the JAK/STAT pathway as a therapeutic target, reinforcing the efficacy of simvastatin as chemotherapeutic drug for the treatment of osteosarcoma. | URI: | http://hdl.handle.net/10553/21075 | ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0087769 | Source: | PLoS ONE [EISSN 1932-6203], v. 9 (1), (Enero 2014) | Rights: | by-nc-nd |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.